v3.26.1
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information

Note 10 - Segment Information

 

The Company has identified two operating segments, diagnostic services and consumer products, based on the manner in which the Company’s CEO, as Chief Operating Decision Maker, assesses performance and allocates resources across the organization. The operating segments are organized in a manner that depicts the difference in revenue generating synergies that include the separate processes, profit generation and growth of each segment. The diagnostic services segment provides diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. The unallocated corporate expenses mainly included professional fees associated with the public company.

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table is a summary of segment information for three months ended March 31, 2026 and 2025 (amounts in thousands):

 

   March 31, 2026   March 31, 2025 
   For the three months ended 
   March 31, 2026   March 31, 2025 
   As Restated      
Net revenues          
Diagnostic services  $-   $- 
Consumer products   1,169    1,431 
Consolidated net revenue   1,169    1,431 
Cost of revenue          
Diagnostic services   -    232 
Consumer products   874    673 
Consolidated cost of revenue   874    905 
Depreciation and amortization expense          
Diagnostic services   -    334 
Consumer products   623    807 
Total Depreciation and amortization expense   623    1,141 
Operating and other expenses          
Diagnostic services   -    168 
Consumer products   511    1,061 
Unallocated corporate   2,962    2,834 
Total  operating and other expenses   3,473    4,063 
Income (loss) from operations, before income taxes          
Diagnostic services   -    (734)
Consumer products   (839)   (1,110)
Unallocated corporate   (2,962)   (2,834)
Total loss from operations, before income taxes   (3,801)   (4,678)
Income tax expense   (1,374)    - 
Total loss from operations, after income taxes   (5,175)   (4,678)
Net loss from continuing operations  $(5,175)  $(4,678)

 

The following table is a summary of segment information as of March 31, 2026 and December 31, 2025 (amounts in thousands):

 

   March 31, 2026   December 31, 2025 
   As Restated      
ASSETS          
Consumer products  $10,973   $11,614 
Unallocated corporate   47,494    48,257 
Total assets  $58,467   $59,871